Nivolumab,Brentuximab
bms,seagen,takeda
['s182']
dr ansell presents os benefit to avd brentuximab in pts with advanced hl compared to abvd. #asco affirms control group in s1826 which is open throughout nctn. 
Lymphoma expert. Director of @WilmotCancer Rochester NY. Editor-in-Chief, Journal of Clinical Oncology @asco_pubs. Tweets and opinions are my own.